Trutek Corp. v. BlueWillow Biologics — Complaint Dismissed With Prejudice After 1,087 Days
Trutek Corp. filed a four-patent infringement action against BlueWillow Biologics over its NanoBio® Protect antimicrobial nanotechnology product in Michigan’s Eastern District. After nearly three years of litigation, the court dismissed Trutek’s complaint with prejudice — permanently closing the door on these claims — while BlueWillow’s counterclaim was dismissed without prejudice.
Three-year nanotech patent battle ends in prejudicial dismissal for Trutek
Trutek Corp. filed suit against BlueWillow Biologics, Inc. on February 10, 2021 in the United States District Court for the Eastern District of Michigan, asserting infringement of four US patents — US8163802B2, US5468488A, US6844005B2, and US5674481A — all directed to antimicrobial and antiviral nanotechnology formulations. The accused products were BlueWillow’s NanoBio droplets and NanoBio® Protect, a topical antimicrobial product platform. ABC Corporation and Robin Roe were named as additional defendants, a placeholder structure commonly used when other infringing parties are not yet identified at filing.
The case closed on February 2, 2024, pursuant to the court’s Opinion and Order granting BlueWillow’s request to dismiss. Trutek’s complaint was dismissed with prejudice — meaning the claims are extinguished and cannot be re-litigated. BlueWillow’s counterclaim, by contrast, was dismissed without prejudice, preserving BlueWillow’s right to reassert those counterclaims in a future proceeding if circumstances warrant. The asymmetric dismissal outcome is notable and typically signals that the court found dispositive grounds against the plaintiff’s position.
A duration of 1,087 days — nearly three years — before dismissal suggests the parties engaged in substantive motion practice rather than early settlement. The fact that dismissal was granted on BlueWillow’s request, rather than by joint stipulation, is consistent with a defendant-driven dispositive motion succeeding on the merits or on procedural grounds. What the public record does not reveal is whether claim construction, summary judgment arguments, or standing issues drove the outcome, nor whether any licensing discussions occurred in parallel.
Filing to dismissal in 1087 days
1,087 days — nearly 3 years from filing to final dismissal order
What the split dismissal order means for Trutek and BlueWillow
Dismissed with prejudice: Trutek’s claims are permanently barred
A dismissal with prejudice is a final adjudication on the merits for res judicata purposes. Trutek Corp. cannot refile these four patent infringement claims against BlueWillow Biologics in any US federal court. The court granted BlueWillow’s request for dismissal, suggesting the defendant successfully argued the plaintiff’s case was legally deficient — whether on standing, claim construction, or substantive infringement grounds.
Plaintiff permanently barred from refilingBlueWillow’s counterclaim survives — dismissed without prejudice
BlueWillow’s counterclaim — likely seeking declaratory judgment of non-infringement or invalidity — was dismissed without prejudice, meaning BlueWillow retains the right to reassert it in future proceedings. This asymmetric outcome is unusual and commercially significant: BlueWillow keeps optionality while Trutek loses all forward litigation rights on these patents against this defendant. It may reflect the court managing judicial economy rather than ruling on the counterclaim’s merits.
BlueWillow retains future counterclaim rightsFour patents spanning decades of antimicrobial nanotech development
Trutek asserted US8163802B2 (filed 2009), US6844005B2 (filed 2002), US5674481A (filed 1995), and US5468488A (filed 1993) — a portfolio spanning roughly 16 years of patent filings. Asserting older patents alongside newer ones is a strategy to broaden claim coverage and complicate invalidity arguments, but it also invites prior art challenges. The age of the earliest patents (US5468488A, US5674481A) may have been a vulnerability in Trutek’s position.
4 patents, filings spanning 1993–20091,087-day timeline suggests contested motion practice, not early settlement
Cases that resolve via early settlement or joint voluntary dismissal typically close well under 365 days. A 1,087-day duration before a defendant-requested dismissal is consistent with extended claim construction proceedings, Markman hearings, or summary judgment briefing. The involvement of Foley & Lardner (BlueWillow’s counsel) — a firm with deep patent litigation experience — suggests a well-resourced defence strategy that likely challenged Trutek’s patents on multiple fronts before the court ultimately sided with the defendant.
Consistent with contested dispositive motionFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Trutek, Corp. | Company | Antimicrobial nanotechnology IP holding company — asserting US8163802B2 and 3 further patentsSearch in Eureka ↗ |
| Defendant | BlueWillow Biologics, Inc. | Company | BlueWillow Biologics, Inc. — developer of NanoBio® nanoemulsion-based antimicrobial productsSearch in Eureka ↗ |
| Plaintiff counsel | Keith L. Altman | Attorney | Counsel for Trutek, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Stanley H. Kremen | Attorney | Counsel for Trutek, Corp.Search in Eureka ↗ |
| Defendant counsel | Alan J. Gocha | Attorney | Counsel for BlueWillow Biologics, Inc.Search in Eureka ↗ |
| Defendant counsel | Liane M. Peterson | Attorney | Counsel for BlueWillow Biologics, Inc.Search in Eureka ↗ |
| Defendant counsel | Nicholas J. Ellis | Attorney | Counsel for BlueWillow Biologics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | Michigan Eastern District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The court’s order creates a deliberate asymmetry: Trutek’s affirmative infringement claims are permanently extinguished by the with-prejudice dismissal, while BlueWillow’s counterclaim — almost certainly seeking invalidity or non-infringement declarations — is preserved. This phrasing suggests the court resolved the case on grounds that directly and finally defeated Trutek’s standing to sue or its substantive case, without reaching the merits of BlueWillow’s counterclaims. For practitioners, the order’s language ‘Granting BlueWillow’s Request to Dismiss’ confirms this was a defendant-initiated outcome, not a mutual or plaintiff-driven resolution.
US8163802B2 and 3 further patents — antimicrobial nanoemulsion formulations
The four patents asserted by Trutek Corp. collectively span a portfolio of antimicrobial and antiviral nanoemulsion technology filed across a 16-year window from 1993 to 2009. US8163802B2, the most recent, covers compositions or methods in the antimicrobial nanotechnology domain. The earlier trio — US5468488A, US5674481A, and US6844005B2 — represent foundational nanotech formulation claims that, if valid and infringed, would capture a broad swath of nanoemulsion-based antimicrobial products. The accused NanoBio® Protect product is a nanoemulsion platform designed for topical antimicrobial applications, placing it squarely within the technical domain these patents address.
Strategically, a four-patent assertion spanning multiple filing generations signals that Trutek sought to create overlapping claim coverage — making it harder for BlueWillow to design around any single patent. However, the age of the earliest filings (US5468488A dates to a 1993 application) creates real invalidity exposure, as prior art from the 1980s and early 1990s in emulsion chemistry and antimicrobial science is extensive. For competitors operating in the nanoemulsion antimicrobial space, the with-prejudice dismissal of Trutek’s claims does not necessarily validate BlueWillow’s technology — it means these specific claims, in this court, were not successfully enforced.
Should you run an FTO analysis against Trutek’s antimicrobial nanoemulsion patents?
Any company developing or commercialising topical antimicrobial products using nanoemulsion delivery technology — particularly in consumer health, infection prevention, or wound care — should assess exposure to Trutek’s patent portfolio. Although Trutek’s claims against BlueWillow were dismissed with prejudice, those four patents (US8163802B2, US5468488A, US6844005B2, US5674481A) remain in force against other parties unless separately challenged or expired. Product teams should not infer blanket clearance from this case outcome.
PatSnap Eureka’s FTO Search Agent can map your formulation claims against each of Trutek’s four asserted patents, identify claim language most likely to create overlap with nanoemulsion antimicrobial compositions, and surface relevant prior art that could support an IPR petition if clearance is uncertain. Eureka’s claim monitoring feature also tracks any continuation or divisional applications that may extend the Trutek portfolio beyond the four patents litigated here — a critical check before product launch or licensing decisions.
Run a freedom-to-operate analysis on US8163802B2 to assess your product’s exposure
Run FTO in Eureka →Similar antimicrobial nanotechnology patent infringement cases in US district courts
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the antimicrobial nanotechnology IP landscape
A prejudicial dismissal of a four-patent assertion after nearly three years carries real implications for IP strategy in the nanoemulsion and antimicrobial formulation sector.
Older patent portfolios face heightened vulnerability in nanotech assertions
Trutek’s portfolio included patents filed as early as 1993 — over 30 years before this case closed. Asserting patents of this age in a fast-moving field like nanotechnology creates significant prior art exposure. Companies holding legacy antimicrobial IP should audit claim scope against modern formulation science before initiating litigation.
Asymmetric dismissal terms signal the defendant held the stronger legal position
When a plaintiff’s claims are dismissed with prejudice while a defendant’s counterclaims survive without prejudice, it typically signals the court found the plaintiff’s case fundamentally deficient. For in-house teams, this pattern suggests BlueWillow’s NanoBio® Protect platform may have successfully distinguished itself from Trutek’s claimed inventions — a useful data point for FTO analysis in the nanoemulsion space.
Trutek v BlueWillow — key questions answered
Trutek’s complaint was dismissed with prejudice, permanently barring Trutek from refiling the same four patent infringement claims against BlueWillow. BlueWillow’s counterclaim was separately dismissed without prejudice, preserving BlueWillow’s right to reassert it in future proceedings.
Trutek asserted four US patents: US8163802B2, US5468488A, US6844005B2, and US5674481A. These patents cover antimicrobial and antiviral nanoemulsion formulation technology filed between 1993 and 2009. The accused products were BlueWillow’s NanoBio droplets and NanoBio® Protect.
The public record confirms the court granted BlueWillow’s request for dismissal in an Opinion and Order dated February 2, 2024, but does not publicly specify the precise grounds — whether standing, claim construction, summary judgment, or procedural deficiency. The with-prejudice outcome for Trutek suggests the court found a dispositive basis against the plaintiff’s position.
The dismissal with prejudice means BlueWillow cannot be sued by Trutek on these four specific patents in future litigation. However, the dismissal does not constitute a judicial ruling that the patents are invalid or that NanoBio® Protect does not infringe — it means Trutek’s claims in this particular case were defeated. Third parties should conduct their own FTO analysis rather than relying on this outcome as general clearance.
The case lasted 1,087 days — approximately three years — from February 10, 2021 to February 2, 2024. This duration is consistent with substantive motion practice including potential claim construction and summary judgment proceedings, rather than early settlement. The case resolved via defendant-requested dismissal rather than mutual agreement, suggesting BlueWillow drove the resolution through successful legal argument.
PatSnap Eureka searches patents and litigation data to answer instantly.